Stockholders' Equity (Details Narrative) - USD ($)			1 Months Ended							2 Months Ended	3 Months Ended	9 Months Ended
	Sep. 12, 2019	Jan. 07, 2019	Mar. 27, 2020	Feb. 24, 2020	Feb. 19, 2020	Feb. 14, 2020	Nov. 25, 2019	Aug. 31, 2019	Aug. 17, 2019	Feb. 29, 2020	Apr. 30, 2020	Apr. 30, 2020	Apr. 30, 2019	Mar. 10, 2020	Jul. 31, 2019
Stock Split				1.4:1
Stock Issued During Period, Value, Issued for Services											$ 50,000	$ 293,600
Issuance of common stock payable, shares												436,121	8,495,924
Issuance of common stock payable, amount												$ 186,972	$ 201,294
Common stock to be issued												410,928	400,928
Common stock issued for conversion debt, Shares												9,719,740
Common stock issued for conversion debt, Value					$ 956,535							$ 4,489,910
Cancellation of common stock	20,375,900
Shares issued as debt issuance cost, shares												343,000
Shares issued as debt issuance cost, value												$ 151,230
Common stock, shares outstanding											79,936,996	79,936,996			78,608,419
Preferred stock, par value														$ 0.001
Preferred stock, Authorized														10,000,000
Preffered stock description			At closing of the first tranche on March 28, 2017, the Company issued 63,000 shares of Series H Preferred Stock for a purchase price of $3,000,000. On December 1, 2018, after payment of the dividend, B-H Sanford, LLC, converted all of its holding of the Company’ Series H Convertible Preferred Stock owned by it into 28,828,953 shares of common stock. On November 30, 2018, Joseph Moscato, the Company’s President and Chief Executive Officer, and Lawrence Salvo, a member of the Company’s Board of Directors, converted all shares of the Company’ Series I Convertible Preferred Stock owned by them receiving the aggregate 7,595,350.
Common stock, par value (in dollars per share)											$ 0.001	$ 0.001		$ 0.001	$ 0.001
Common stock, shares authorized											750,000,000	750,000,000		750,000,000	750,000,000
Generex
Common stock, shares outstanding									1,905,912
NGIO
Common stock, shares outstanding									476,478
Vendors
Stock Issued During Period, Shares Issued for Services										669,803
Stock Issued During Period, Value, Issued for Services										$ 293,600
Investors | Equity Purchase Agreement [Member]
Common stock purchased							$ 40,000,000
Number of common stock issued							1,719,901
Minimum [Member]
Stock Price											$ 0.26	$ 0.26
Minimum [Member] | Vendors
Stock Price										$ 0.44
Maximum [Member]
Stock Price											$ 0.51	$ 0.51
Maximum [Member] | Vendors
Stock Price										$ 0.46
Series I Preferred Stock [Member]
Preferred stock, par value			$ 1,000
Preferred stock, Authorized			109,000
Series H Preferred Stock [Member]
Preferred stock, par value			$ 47.61
Preferred stock, Authorized			6,000
Medisource
Common stock issued for acquisition								400,000
Stock Price								$ 2.50
Pantheon [Member]
Common stock issued for acquisition								560,000
Stock Price								$ 2.50
Olaregen
Payroll related liability						$ 32,212
LOI Terms		Pursuant to the Company’s acquisition of Olaregen on January 7, 2019 to acquire a 51% interest, the Company was issued 3,282,632 shares of Olaregen common stock from Olaregen shareholders. In May 2019, the Company issued 4,000,000 shares of common stock contributed and provided by the Friends of Generex Trust and a $2 million note payable for the acquisition of 592,683 shares of Series A Preferred Stock of Olaregen pursuant to a Stock Purchase Agreement entered into January 14, 2019 subject to the approval of the Board of Directors of Olaregen and consummated on May 10, 2019. The provided shares by the Friends of Generex Trust were already issued and outstanding and did not result in any expense of the Company. Since these shares were transferred, to the shareholders of Olaregen, by an existing shareholder to settle an obligation of the Company, the value of the shares provided by the Friends of the Generex Trust to settle the debt was reflected in the financial statements as an addition to contributed (paid-in) capital. After completion Share Exchange Agreement on August 16, 2019, the Company owned 51% of Olaregen.
Common stock, shares outstanding						5,950,000					7,855,912	7,855,912
Olaregen | Share Exchange Agreement
Number of shares exchanged									900,000
NGIO
Common stock, shares outstanding						2,765,000					400,000,000	400,000,000
Non-controlling interest											38,357,038	38,357,038
Percentage of non-controlling interest											9.59%	9.59%
Regentys
LOI Terms		Pursuant to the Company’s acquisition of Regentys on January 7, 2019 to acquire a 51% interest, the Company was issued 12,048,161 shares of Regentys common stock. As of January 31, 2020, Regentys had a total of 18,623,278 shares of common stock and 2,793,192 Series A voting preferred stock for a total of 21,416,470 total voting shares outstanding. As such, there are 9,368,309 of shares that belong to non-controlling interest shareholders which represents a 43.74% non-controlling interest.